102 related articles for article (PubMed ID: 1979247)
1. In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates.
Starling JJ; Maciak RS; Hinson NA; Hoskins J; Laguzza BC; Gadski RA; Strnad J; Rittmann-Grauer L; DeHerdt SV; Bumol TF
Cancer Res; 1990 Dec; 50(23):7634-40. PubMed ID: 1979247
[TBL] [Abstract][Full Text] [Related]
2. In vivo expression of P-glycoprotein in a human colon carcinoma xenograft is modulated by therapy with free and monoclonal antibody-conjugated vinca alkaloids.
Hilselberger Kanitz M; Mastro JM; Moore RE; Starling JJ
Anticancer Res; 1994; 14(3A):857-68. PubMed ID: 7915508
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes.
Starling JJ; Maciak RS; Law KL; Hinson NA; Briggs SL; Laguzza BC; Johnson DA
Cancer Res; 1991 Jun; 51(11):2965-72. PubMed ID: 2032233
[TBL] [Abstract][Full Text] [Related]
4. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft.
Rittmann-Grauer LS; Yong MA; Sanders V; Mackensen DG
Cancer Res; 1992 Apr; 52(7):1810-6. PubMed ID: 1348013
[TBL] [Abstract][Full Text] [Related]
5. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.
Spearman ME; Goodwin RM; Apelgren LD; Bumol TF
J Pharmacol Exp Ther; 1987 May; 241(2):695-703. PubMed ID: 3494841
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.
Apelgren LD; Zimmerman DL; Briggs SL; Bumol TF
Cancer Res; 1990 Jun; 50(12):3540-4. PubMed ID: 2340502
[TBL] [Abstract][Full Text] [Related]
7. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
Iwahashi T; Okochi E; Ariyoshi K; Watabe H; Amann E; Mori S; Tsuruo T; Ono K
Cancer Res; 1993 Nov; 53(22):5475-82. PubMed ID: 8106147
[TBL] [Abstract][Full Text] [Related]
8. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
Berlion M; Arvelo F; Leonce S; Bourgeois Y; Rigaudy P; Bizzari JP; Poupon MF
In Vivo; 1993; 7(5):399-405. PubMed ID: 7906553
[TBL] [Abstract][Full Text] [Related]
10. KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.
Bumol TF; Baker AL; Andrews EL; DeHerdt SV; Briggs SL; Spearman ME; Apelgren LD
Targeted Diagn Ther; 1988; 1():55-79. PubMed ID: 2979063
[No Abstract] [Full Text] [Related]
11. Development of a dual label fluorescence technique that can be utilized to elucidate the mechanism of action of monoclonal antibody-drug conjugates.
Starling JJ; Hinson NA; Marder P; Maciak RS; Laguzza BC; Corvalan JR; Smith W
Cancer Res; 1988 Nov; 48(21):6211-6. PubMed ID: 3048656
[TBL] [Abstract][Full Text] [Related]
12. Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D.
Johnson DA; Laguzza BC
Cancer Res; 1987 Jun; 47(12):3118-22. PubMed ID: 3495327
[TBL] [Abstract][Full Text] [Related]
13. The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model.
Stastny JJ; Das Gupta TK
Cancer Res; 1993 Dec; 53(23):5740-4. PubMed ID: 8242630
[TBL] [Abstract][Full Text] [Related]
14. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
15. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of L/1C2-4-desacetylvinblastine-3-carboxhydrazide immunoconjugate in xenografts.
Johnson DA; Baker AL; Laguzza BC; Fix DV; Gutowski MC
Cancer Res; 1990 Mar; 50(6):1790-4. PubMed ID: 2306731
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cells.
Danks MK; Metzger DW; Ashmun RA; Beck WT
Cancer Res; 1985 Jul; 45(7):3220-4. PubMed ID: 3891080
[TBL] [Abstract][Full Text] [Related]
18. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
Yokota S; Hara H; Luo Y; Seon BK
Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Mirski SE; Gerlach JH; Cole SP
Cancer Res; 1987 May; 47(10):2594-8. PubMed ID: 2436751
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Hill AB; Beck WT; Trent JM
Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]